Sanofi pins hopes on new drugs after setbacks
Some investors have voiced discontent with the group’s product pipeline
Paris — French pharmaceuticals group Sanofi said on Wednesday it had suffered from low uptake for a new cholesterol drug and from concerns about a dengue vaccine but expressed confidence its pipeline of new products would support growth. The world’s sixth-largest drug maker, which is battling to contain the fallout from a safety row in the Philippines over dengue vaccine Dengvaxia, said that it expected to file nine regulatory submissions in the next 18 months. Some investors have voiced discontent with the group’s product pipeline and its failure to engage in a large acquisition since it appointed Olivier Brandicourt as CE in 2015. Sanofi is under pressure to stand out in research and development as its diabetes division still has to overcome pricing constraints in the US, where its blockbuster insulin medication Lantus has lost its patent. Brandicourt said at a company investor day that the group was "on track" to sell its European generic drugs unit in "the coming year", a long-a...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.